B+
Bull case
25%
Probability
Target price
$590.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
CHE
ChemedBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$545.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$475.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+69.0
Score
AI commentary
The SEC-filed Q2 release provides concrete primary-source confirmation of stronger results and raised guidance. The Benzinga quote page showed CHE at $534.79 at the 2026-07-30 close, down 0.85% that day; this is a post-print observation, but the packet does not establish a clean earnings-day attribution. Analyst reaction is limited to the reported RBC target increase and maintained Sector Perform rating, so the muted price response and thin revision breadth support continued monitoring rather than a higher-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-07-31
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-07-28eventQ2 earnings and raised full-year guidanceMedium impact
Chemed reported Q2 revenue of $673.3 million, adjusted diluted EPS of $6.06, and increased full-year guidance, driven mainly by VITAS outperformance. [#SEC-8K-2026-07-28]
2026-10-29catalystRoto-Rooter remains an offsetMedium impact
Roto-Rooter revenue increased 3.3%, but adjusted EBITDA was essentially flat and margin declined 77 basis points, leaving execution and margin recovery as near-term watch items. [#SEC-8K-2026-07-28]
2026-12-31catalystVITAS growth and lower Medicare Cap burdenMedium impact
VITAS admissions rose 9.0%, ADC rose 6.1%, adjusted EBITDA margin expanded 196 basis points, and Medicare Cap billing limitation fell sharply year over year. [#SEC-8K-2026-07-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology